請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45874
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張上淳(Shan-Chwen Chang) | |
dc.contributor.author | Ching-Lan Lu | en |
dc.contributor.author | 路景蘭 | zh_TW |
dc.date.accessioned | 2021-06-15T04:47:50Z | - |
dc.date.available | 2015-09-09 | |
dc.date.copyright | 2010-09-09 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-04 | |
dc.identifier.citation | 1. Chen CJ, Huang YC, Su LH, Lin TY. Nasal carriage of Streptococcus pneumoniae in healthy children and adults in northern Taiwan. Diagn Microbiol Infect Dis 2007;59(3):265-9.
2. Lo WT, Wang CC, Yu CM, Chu ML. Rate of nasopharyngeal carriage, antimicrobial resistance and serotype of Streptococcus pneumoniae among children in northern Taiwan. J Microbiol Immunol Infect 2003;36(3):175-81. 3. Edwards KM, Griffin MR. Great expectations for a new vaccine. N Engl J Med 2003;349(14):1312-4. 4. Fedson DS, Scott JA. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999;17 Suppl 1:S11-8. 5. Chen CJ, Lin CL, Chen YC, et al. Host and microbiologic factors associated with mortality in Taiwanese children with invasive pneumococcal diseases, 2001 to 2006. Diagn Microbiol Infect Dis 2009;63(2):194-200. 6. Siu LK, Chu ML, Ho M, Lee YS, Wang CC. Epidemiology of invasive pneumococcal infection in Taiwan: antibiotic resistance, serogroup distribution, and ribotypes analyses. Microb Drug Resist 2002;8(3):201-8. 7. Chen YY, Yao SM, Chou CY, et al. Surveillance of invasive Streptococcus pneumoniae in Taiwan, 2002-2003. J Med Microbiol 2006;55:1109-14. 8. Lin WJ, Lo WT, Chou CY, et al. Antimicrobial resistance patterns and serotype distribution of invasive Streptococcus pneumoniae isolates from children in Taiwan from 1999 to 2004. Diagn Microbiol Infect Dis 2006;56(2):189-96. 9. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004;117 Suppl 3A:3S-15S. 10. Chiu CH, Su LH, Huang YC, et al. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 2007;51(9):3404-6. 11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI document M100-S18. CLSI, Wayne, PA, USA, 2008. 12. Su LH, Wu TL, Kuo AJ, Chia JH, Chiu CH. Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000-07: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18. J Antimicrob Chemother 2009;64(2):336-42. 13. Gilks CF, Ojoo SA, Ojoo JC, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996;347(9003):718-23. 14. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998;12(16):2177-84. 15. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309(8):453-8. 16. Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988;158(6):1268-76. 17. Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS 1989;3(1):37-9. 18. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007;20(1):11-5. 19. Feldman C. Pneumonia associated with HIV infection. Curr Opin Infect Dis 2005;18(2):165-70. 20. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004 ;4(7):445-55. 21. Redd SC, Rutherford GW, 3rd, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990;162(5):1012-7. 22. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004;38(11):1623-8. 23. Tasslimi A, Wenger P, Pentakota SR, Brimacombe M, Burday M, Sinha A. Invasive pneumococcal disease in an underimmunized, high HIV prevalence population. J Infect 2008;56(2):99-102. 24. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992;327(26):1842-8. 25. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001;32(5):794-800. 26. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005 11;165(13):1533-40. 27. Lanzafame M, Lattuada E, Gottardi M, Antolini D, Concia E, Vento S. Discontinuation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy: clinical implications in patients on CD4 T-cell-guided treatment interruption. AIDS 2007;21(10):1384-6. 28. Edge MD, Rimland D. Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole. AIDS 1996;10(14):1635-9. 29. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis 1999;180(6):1809-18. 30. Wininger DA, Fass RJ. Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia. Antimicrob Agents Chemother 2002;46(2):594-7. 31. Hsueh PR, Teng LJ, Wu TL, et al. Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob Agents Chemother 2003;47(7):2145-51. 32. Fung CP, Hu BS, Lee SC, et al. Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: an island-wide surveillance study between 1996 and 1997. J Antimicrob Chemother 2000;45(1):49-55. 33. Hsieh YC, Chang KY, Huang YC, et al. Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 2008;52(6):2266-9. 34. Centers for Disease Control and Prevention. Recommendations of the immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1989;38:64-68, 73-76. 35. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46:1-24. 36. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95. 37. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46. 38. Hsieh YC, Lin PY, Chiu CH, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009;27(40):5513-8. 39. Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008;47(11):1388-95. 40. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009;49(2):205-12. 41. Dortet L, Ploy MC, Poyart C, Raymond J. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 2009;65(1):49-57. 42. Gertz RE, Jr., Li Z, Pimenta FC, et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010;201(5):770-5. 43. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001;19(32):4780-90. 44. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351(9100):399-403. 45. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003;22(1):96-103. 46. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46(7):1015-23. 47. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9):1318-25. 48. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis 2009;49(2):241-8. 49. Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in solid organ transplant recipients--10-year prospective population surveillance. Am J Transplant 2007;7(5):1209-14. 50. Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001;32(2):307-10. 51. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000;181(2):757-60. 52. Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008;47(7):885-92. 53. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003;187(10):1639-45. 54. Nichol KL. Ten-year durability and success of an organized program to increase influenza and pneumococcal vaccination rates among high-risk adults. Am J Med 1998;105(5):385-92. 55. Ochoa-Gondar O, Vila-Corcoles A, Ansa X, et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 2008;26(16):1955-62. 56. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61(3):189-95. 57. Dransfield MT, Nahm MH, Han MK, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(6):499-505. 58. '1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).' MMWR Recomm Rep 48(RR-10): 1-59, 61-6. 59. Veras MA, Enanoria WT, Castilho EA, Reingold AL. Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study. BMC Infect Dis 2007;7:119. 60. Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008 ;46(7):1093-100. 61. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996 ;173(4):857-62. 62. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000;160(17):2633-8. 63. Penaranda M, Falco V, Payeras A, et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007;45(7):e82-7. 64. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004;22(15-16):2006-12. 65. Ballet JJ, Sulcebe G, Couderc LJ, et al. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol 1987;68(3):479-87. 66. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991;84(2):185-9. 67. Carson PJ, Schut RL, Simpson ML, O'Brien J, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis 1995 ;172(2):340-5. 68. French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, Janoff EN. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. AIDS 1998;12(13):1683-9. 69. Falco V, Jordano Q, Cruz MJ, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 2006;24(14):2567-74. 70. Hung CC, Chang SY, Su CT, et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010;11(1):54-63. 71. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003;37(3):438-47. 72. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994;8(4):469-76. 73. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999;18(5-6):524-30. 74. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000;355(9221):2106-11. 75. Chen M, Ssali F, Mulungi M, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008;26(38):4962-8. 76. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001;20(3-4):545-53. 77. Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007;21(18):2425-34. 78. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362(9):812-22. 79. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines WHO Technical Report Series No. 927, Annex 2. World Health Organization; 2005. http://www.who.int/biologicals /publications/trs/areas/vaccines/pneumo/en/index.html. 80. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000;19(7-8):886-94. 81. Rabian C, Tschope I, Lesprit P, et al. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults. Clin Infect Dis 2010;50(8):1174-83. 82. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010;201(10):1570-9. 83. Vakevainen M, Soininen A, Lucero M, et al. Serotype-Specific Hyporesponsiveness to Pneumococcal Conjugate Vaccine in Infants Carrying Pneumococcus at the Time of Vaccination. J Pediatr 2010 Jun 12. 84. Sogaard OS, Schonheyder HC, Bukh AR, et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010;24(9):1315-22. 85. Cooper CL, Davis HL, Angel JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005;19(14):1473-9. 86. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008;46(8):1310-4. 87. Sogaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010;51(1):42-50. 88. King JC, Jr., Vink PE, Farley JJ, et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997;99:575-80. 89. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003;112:66-73. 90. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996;174(6):1191-9. 91. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-37. 92. Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine 2002;20(31-32):3720-4. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45874 | - |
dc.description.abstract | 愛滋病毒感染者較沒有感染愛滋病毒的一般人容易發生侵入性肺炎鏈球菌疾病。在沒有高效能的抗病毒藥物組合治療(俗稱雞尾酒療法)的年代,愛滋病毒感染者感染侵入性肺炎鏈球菌疾病的風險為一般民眾的100倍;然而,愛滋病毒感染者在接受高效能的抗病毒藥物治療後,感染侵入性肺炎鏈球菌疾病的風險仍為一般民眾的35到60倍。有鑑於此,美國疫苗接種諮詢委員會建議愛滋病毒感染者施打23價肺炎鏈球菌疫苗。雖然多數文獻支持23價肺炎鏈球菌多醣體疫苗可增加愛滋病毒感染者保護力,但仍有文獻指出23價肺炎鏈球菌多醣體疫苗所引起的抗體效價受到多重因子影響,例如:在未同時接受雞尾酒治療病患或是CD4細胞數量較低的愛滋病毒感染者,接種23價肺炎鏈球菌多醣體疫苗後產生抗體反應會比較差。此外,在一般病患接種23價肺炎鏈球菌多醣體疫苗後,血液中可以維持足夠保護性的抗體濃度的時間大約是五年,但是在愛滋病毒感染病患,這個期間可能不到三年。西元2000年美國食品藥物管制局通過7價蛋白結合型肺炎鏈球菌疫苗上市,適用於2歲以下幼童和2-9歲的高危險群,共需接種四劑。國外研究發現愛滋病毒感染者施打7價蛋白結合型肺炎鏈球菌疫苗後,其抗體效價比接種23價肺炎鏈球菌多醣體疫苗的病患來得高。但是目前仍不清楚成人該施打多少劑的7價蛋白結合型肺炎鏈球菌疫苗。
本研究將愛滋病毒感染者分為兩個組群,一組80人接種兩劑7價蛋白結合型肺炎鏈球菌疫苗,兩劑間隔一個月;另一組79人只接種一劑疫苗,接種後每三個月追蹤血請抗體濃度,共追蹤一年。血清抗體濃度是以ELISA方法偵測受試者血清中對血清型6B、14、19F、和23F四種肺炎鏈球菌血清型的抗體濃度。本研究的第一個目標為分析比較兩組疫苗接種者血清抗體上升兩倍以上的比例是否有所不同,第二個目標則是評估影響抗體產生的相關因子;另外,我們也評估7價蛋白結合型肺炎鏈球菌疫苗對愛滋病毒感染者短期內CD4細胞數目和病毒量的影響。 我們的追蹤研究結果發現,愛滋病毒感染者在接種疫苗後第十二個月,兩劑組中有85%的受試者對至少一種肺炎鏈球菌血清型產生反應,57.5%對至少兩種肺炎鏈球菌血清型產生反應,28.8%對至少三種肺炎鏈球菌血清型產生反應,13.8%對四種肺炎鏈球菌血清型都產生反應;一劑組中則有72.2%對至少一種肺炎鏈球菌血清型產生反應,44.3%對至少兩種肺炎鏈球菌血清型產生反應,27.8%對至少三種肺炎鏈球菌血清型產生反應,6.3%對四種肺炎鏈球菌血清型都產生反應。在不同血清型方面,施打7價蛋白結合型肺炎鏈球菌疫苗後第六個月,血清型14的反應率最高(兩劑組:66.2%;一劑組:64.6%),再來是血清型23F(兩劑組:66.2%;一劑組:59.5%),血清型19F(兩劑組:46.8%;一劑組:35.4%),而血清型6B最差(兩劑組:42.9%;一劑組:31.7%)。在第十二個月,血清型14的反應率在兩劑組為57.0%,一劑組為57.0%,血清型23F在兩劑組為60.0%,一劑組為45.6%,血清型19F在兩劑組為33.8%;一劑組為26.6%,血清型6B在兩劑組為32.5%;一劑組為21.5%。在施打一劑或兩劑疫苗後第三個月比較容易對四種肺炎鏈球菌血清型都發生反應,打兩劑疫苗者在第六個月比較容易對四種肺炎鏈球菌血清型都發生反應。另外,最低點CD4細胞數目越高者、異性戀者、和B型肝炎帶原者也比較容易對四種肺炎鏈球菌血清型都發生反應。在施打疫苗後第三個月受試者在血清型6B、14、和19F都可以觀察到基礎血清抗體量越高的病患,之後越不容易達到兩倍以上的增加;之前感染過B型肝炎的受試者,也較不容易發生反應;在接受兩劑疫苗的受試者,第三個月的血清型6B抗體反應和第六個月的血清型19F抗體反應比較好,除此之外並沒有差別。 總結,愛滋病毒感染者在接種7價蛋白結合型肺炎鏈球菌疫苗後一年,根據肺炎鏈球菌血清型的不同,反應率介於21.5%至60.0%間。接種兩劑7價蛋白結合型肺炎鏈球菌疫苗的愛滋病毒感染者,抗體的持久度並不會比僅接受一劑者來得好。 | zh_TW |
dc.description.abstract | Clinical studies have shown that vaccination with pneumococcal conjugate vaccine (PCV) decreases incidence of invasive pneumococcal diseases among HIV-infected children and adults. However, longitudinal follow-up of serologic responses to conjugated pneumococcal vaccination are rarely performed among HIV-infected adult patients receiving combination antiretroviral therapy (CART).
From October 2008 to April 2009, 159 HIV-infected adult patients were enrolled who had never received pneumococcal vaccine before, were not taking immunosuppressives, or had no active opportunistic illnesses. Eighty patients received two doses of 7-valent PCV given one month apart and 79 received one dose. Anticapsular antibody responses against 4 serotypes were examined (6B, 14, 19F, and 23F) at the 3rd, 6th, 9th, and 12th month following vaccination with the use of ELISA after absorption with 10 μg/ml cell-wall polysaccharide and 30 μg/ml 22F polysaccharide. Significant antibody responses were defined as 2-fold or greater increase of antibody level following vaccination compared to baseline. Antibody response rates following vaccination varied with the 4 serotypes examined during follow-up. At 6th month, the rate was highest for serotype 23F (1-dose vs. 2-dose, 60.0% vs. 61.8%, P=0.75), followed by 14 (58.2% vs. 63.6%, P=0.47), 19F (36.4% vs. 49.1%, P=0.15), and 6B (34.5% vs. 40.0%, P=0.50). At 12th month, the 1-dose vs. 2-dose response rate for serotype 23F. 14, 19F, and 6B was 45.5% vs. 56.4% (P=0.25), 52.7% vs. 52.7% (P=0.99), 29.1 vs. 40.0 (P=0.23), and 23.6% vs. 30.9% (P=0.39), respectively. No significant differences of serotype-specific IgG concentrations for each serotype at the 4 time points were observed between patients receiving 1 dose and those receiving 2 doses of PCV except for serotype 6B at third month. Higher nadir CD4 count, heterosexual patients, and hepatitis B carrier were more likely to mount antibody responses to all 4 pneumococcal serotypes tested. Patients who received 2 doses of vaccine had a higher response rate at sixth month compared to patients who received 1 dose. In this longitudinal follow-up study of 7-valent conjugated pneumococcal vaccination, the response rate to different serotypes one year after PCV vaccination ranged from 21.5% to 60.0% among HIV-infected patients. Patients who received 2 doses of PCV achieved similar serological responses against 4 serotypes to those who received 1 dose of PCV. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:47:50Z (GMT). No. of bitstreams: 1 ntu-99-P97421005-1.pdf: 663611 bytes, checksum: 151396e01505d276a8b670059b2996ac (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………………………2
誌謝……………………………………………………………………………………3 中文摘要 ....................................................................................................................... 5 Abstract ......................................................................................................................... 7 第一章:前言 ............................................................................................................. 13 1.1 肺炎鏈球菌微生物學 ................................................................................... 13 1.2 肺炎鏈球菌之流行病學 ............................................................................... 13 1.3 肺炎鏈球菌感染之治療 ............................................................................... 15 1.4 愛滋病毒感染者與肺炎鏈球菌之關係 ....................................................... 16 1.5 肺炎鏈球菌疫苗介紹 ................................................................................... 17 1.6 兩種肺炎鏈球菌疫苗在健康年長者和免疫不全族群之比較 ................... 20 1.6.1 健康年長者 ....................................................................................... 20 1.6.2 器官移植患者 ................................................................................... 20 1.6.3 慢性肺阻塞疾病患者 ....................................................................... 21 1.7 兩種肺炎鏈球菌疫苗在愛滋病毒感染者之比較 ....................................... 22 1.8 研究目的 ....................................................................................................... 24 第二章:研究方法與材料 ......................................................................................... 25 2.1 實驗設計及研究對象 ................................................................................... 25 2.2 受試者CD4 細胞數量以及血清HIV 病毒量檢測 .................................... 25 2.3 疫苗施打 ....................................................................................................... 25 2.4 副作用評估 ................................................................................................... 26 2.5 檢體蒐集與血清抗體檢測 ........................................................................... 26 2.6 定義................................................................................................................ 27 2.7 統計分析 ....................................................................................................... 27 第三章:研究結果 ..................................................................................................... 29 3.1 受試者基本資料分析 ................................................................................... 29 3.2 兩組受試者接種疫苗後,血清抗體反應比較 .......................................... 29 3.2.1 兩組受試者接種疫苗後,對不同數目的肺炎鏈球菌血清型,產生 兩倍以上抗體反應的比較 ......................................................................... 29 3.2.1.1 兩組受試者接種疫苗後,至少對一種血清型產生兩倍以上抗體上升的反應比率(Intent-to-treat analysis) .............................. 29 3.2.1.2 兩組受試者接種疫苗後,至少對兩種血清型產生兩倍以上抗體上升的反應比率(Intent-to-treat analysis) .............................. 30 3.2.1.3 兩組受試者接種疫苗後,至少對三種血清型產生兩倍以上抗體上升的反應比率(Intent-to-treat analysis) .............................. 31 3.2.1.4 兩組受試者接種疫苗後,對四種血清型都產生兩倍以上抗體上升的反應比率(Intent-to-treat analysis) ................................ 32 3.2.2 兩組受試者接種疫苗後,對四種肺炎鏈球菌血清型,都產生兩倍以上抗體反應的相關因子之多變數分析 ...................................... 33 3.2.3 兩組受試者接種疫苗後,對不同種的肺炎鏈球菌血清型,產生兩倍以上抗體反應的比較 .................................................... 33 3.2.3.1 血清型6B ................................................................................ 33 3.2.3.2 血清型14................................................................................. 34 3.2.3.3 血清型19F .............................................................................. 35 3.2.3.4 血清型23F .............................................................................. 35 3.3 副作用分析 ................................................................................................... 36 3.3.1 局部及系統性副作用 ........................................................................ 36 3.3.2 接種疫苗前後CD4 細胞數量之變化 ............................................... 36 3.3.3 接種疫苗前後HIV 病毒量之變化 ................................................... 37 第四章:討論 ............................................................................................................. 38 第五章:結論 ............................................................................................................. 43 第六章:參考文獻 ..................................................................................................... 44 第七章:表 ................................................................................................................. 56 表一.CLSI 對於抗藥性肺炎鏈球菌的定義 .................................................... 56 表二.23 價肺炎鏈球菌多醣體疫苗和7 價蛋白結合型肺炎鏈球菌疫苗健康年長者效力(effectiveness)的比較 ........................................ 57 表三.23 價肺炎鏈球菌多醣體疫苗和7 價蛋白結合型肺炎鏈球菌疫苗在接受器官移植患者的效力(effectiveness)的比較 ............................... 58 表四.7 價蛋白結合型肺炎鏈球菌疫苗施打於愛滋病毒感染者的效力之研究........................................................................ 59 表五.兩組受試者臨床資料分析比較.............................................................. 60 表六.副作用發生之單變數分析...................................................................... 61 表七A.兩組受試者接種疫苗後,至少對一種肺炎鏈球菌血清型產生兩倍以上抗體上升的反應比率之單變數分析.............................................................. 62 表七B.兩組受試者接種疫苗後,至少對兩種肺炎鏈球菌血清型產生兩倍以上抗體上升的反應比率之單變數分析.............................................................. 63 表七C.兩組受試者接種疫苗後,至少對三種肺炎鏈球菌血清型產生兩倍以上抗體上升的反應比率之單變數分析.............................................................. 64 表七D.兩組受試者接種疫苗後,對四種肺炎鏈球菌血清型都產生兩倍以上抗體上升的反應比率之單變數分析.................................................................. 65 表八.以Generalized estimation equation (GEE) 分析兩組受試者在接種疫苗後,對四種血清型皆發生發生兩倍以上抗體相關因子............................... 66 表九A.以Generalized estimation equation (GEE) 分析兩組受試者在接種疫苗後,對血清型6B 發生兩倍以上抗體相關因子 ..................................... 67 表九B.以Generalized estimation equation (GEE) 分析兩組受試者在接種疫苗後,對血清型14 發生兩倍以上抗體相關因子...................................... 68 表九C.以Generalized estimation equation (GEE) 分析兩組受試者在接種疫苗後,對血清型19F 發生兩倍以上抗體相關因子 .................................... 69 表九D.以Generalized estimation equation (GEE) 分析兩組受試者在接種疫苗後,對血清型23F 發生兩倍以上抗體相關因子 .................................... 70 第八章:圖 ................................................................................................................. 71 圖一.七價結合型肺炎鏈球菌疫苗施打臨床試驗流程圖.............................. 71 圖二A.接種疫苗前後CD4 細胞數量之變化 ................................................ 72 圖二B.接種疫苗前後HIV 病毒量之變化 ..................................................... 73 圖三A.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,至少對一種血清型產生兩倍以上抗體上升的反應比率.......... 74 圖三B.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,至少對兩種血清型產生兩倍以上抗體上升的反應比率.......... 75 圖三C.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,至少對三種血清型產生兩倍以上抗體上升的反應比率.......... 76 圖三D.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,對四種血清型皆產生兩倍以上抗體上升的反應比率.............. 77 圖四A.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,對血清型6B 產生兩倍以上抗體上升的反應比率 ................... 78 圖四B.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,對血清型14 產生兩倍以上抗體上升的反應比率.................... 79 圖四C.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,對血清型19F 產生兩倍以上抗體上升的反應比率 ................. 80 圖四D.兩組受試者接種第一劑疫苗後第三個月、第六個月、第九個月、和第十二個月,對血清型23F 產生兩倍以上抗體上升的反應比率 ................. 81 | |
dc.language.iso | zh-TW | |
dc.title | 愛滋病毒感染者施打七價結合型肺炎鏈球菌疫苗血清反應之一年追蹤 | zh_TW |
dc.title | One-year Longitudinal Follow-up of Serologic Responses to Vaccination with 7-Valent Pneumococcal Conjugate Vaccine among HIV-infected Adult Patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 張淑媛(Sui-Yuan Chang) | |
dc.contributor.oralexamcommittee | 高嘉宏,柯文謙 | |
dc.subject.keyword | 愛滋病毒感染,肺炎鏈球菌,肺炎鏈球菌疫苗,7價蛋白結合型肺炎鏈球菌疫苗,血清抗體反應, | zh_TW |
dc.subject.keyword | human immunodeficiency virus,Streptococcus pneumoniae,invasive pneumococcal disease,pneumococcal vaccine,7-valent pneumococcal conjugate vaccine, | en |
dc.relation.page | 81 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 648.06 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。